• Primary care use of KidneyIntelX in early stage CKD improved clinical care delivery and outcomes. First-in-class, bioprognostic™ KidneyIntelX provided clear direction for primary care physicians to slow or stop progression of chronic kidney disease in adult diabetes patients.


  • Published real world evidence demonstrates KidneyIntelX™ improved clinical decisions and outcomes in high-risk patients with early-stage diabetic kidney disease. Risk scoring by KidneyIntelX resulted in a 4.5-fold increase in new drug prescriptions (for SGLT2i inhibitors) for high risk compared to low risk patients, an observed reduction of HbA1c levels in the highest risk patients, an overall increased use of antihypertensive therapeutics, and an observed early reduction in albumin to creatine ratio levels in the low and intermediate risk groups.


  • KidneyIntelX clinical utility and health economics validated in multiple data releases at American Society of Nephrology. First clinical utility findings with multi-year real world evidence from a major health system was shared. Results underscore the value of the KidneyIntelX™ platform in improving cost economics for the Medicare population.